DGAP-Adhoc: Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic
|
DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic
29-Oct-2020 / 14:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
| Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic |
Jena, October 29, 2020
Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approximately EUR 1,335.5 million in fiscal year 2019/20 (previous year EUR 1,459.3 million) and has thereby exceeded the forecast of approx. EUR 1.3 billion provided on July 15, 2020. This corresponds to a decline of -8.5% vs. the past year. After adjustment for currency effects[1], the decline amounted to -8.7%. In the fourth quarter of 2019/20, revenue reached EUR 367.6 million (Q4 2018/19: EUR 431.7 million), a decline of -14.9%. After adjustment for currency effects, the decline amounted to around -14.5%.
Earnings before interest and taxes (EBIT)[2] amounted to EUR 177.6 million in fiscal year 2019/20 (previous year EUR 264.7 million). EBIT margin (EBIT / revenue) was 13.3% (previous year 18.1%). In the fourth quarter of 2019/20, EBIT amounted to EUR 65.7 million (Q4 2018/19: 80.5 million), EBIT margin was 17.9% (Q4 2018/19: 18.6%).
Earnings per share (EPS)[3] declined to EUR 1.37 (previous year EUR 1.79). In the fourth quarter of 2019/20, EPS was EUR 0.60 (Q4 2018/19: EUR 0.57).
Full results for fiscal year 2019/20 will be provided on Dec 11, 2020.
Carl Zeiss Meditec broadly expects a recovery of its markets in fiscal year 2020/21 and thereby a return to growth in revenue and EBIT. Due to the current trend in COVID-19 infections in Europe and North America, an additional impact from the pandemic cannot be ruled out at the outset of the new fiscal year, though. From today's point of view, the company expects revenue and EBIT for the first months of the new fiscal year 2020/21 to come in below last year's values for the same period. |
Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]
[1] Currency-adjusted sales growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2018/19, p. 76 for reconciliation).
[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2018/19, p. 76 for reconciliation).
29-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
| Language: |
English |
| Company: |
Carl Zeiss Meditec AG |
|
Göschwitzer Str. 51-52 |
|
07745 Jena, Germany |
|
Germany |
| Phone: |
+49 (0)3641 220-0 |
| Fax: |
+49 (0)3641 220-112 |
| E-mail: |
[email protected] |
| Internet: |
www.zeiss.de/meditec-ag/ir |
| ISIN: |
DE0005313704 |
| WKN: |
531370 |
| Indices: |
MDAX, TecDAX |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1144021 |
| |
| End of Announcement |
DGAP News Service |
1144021 29-Oct-2020 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
1.189,90 |
1.280,86 |
1.459,32 |
1.335,45 |
1.646,79 |
1.902,84 |
2.089,30 |
| EBITDA1,2 |
205,07 |
228,41 |
313,03 |
237,98 |
435,20 |
466,65 |
422,19 |
| EBITDA-Marge3 |
17,23 |
17,83 |
21,45 |
17,82 |
26,43 |
24,52 |
|
| EBIT1,4 |
180,83 |
197,13 |
264,66 |
177,55 |
373,61 |
396,88 |
348,12 |
| EBIT-Marge5 |
15,20 |
15,39 |
18,14 |
13,30 |
22,69 |
20,86 |
16,66 |
| Jahresüberschuss1 |
135,78 |
126,23 |
160,58 |
123,42 |
237,52 |
295,91 |
292,01 |
| Netto-Marge6 |
11,41 |
9,86 |
11,00 |
9,24 |
14,42 |
15,55 |
13,98 |
| Cashflow1,7 |
37,73 |
187,21 |
219,63 |
178,53 |
362,66 |
188,20 |
250,86 |
| Ergebnis je Aktie8 |
1,57 |
1,41 |
1,79 |
1,37 |
2,64 |
3,29 |
3,25 |
| Dividende8 |
0,55 |
0,55 |
0,65 |
0,50 |
0,90 |
1,10 |
0,42 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Carl Zeiss Meditec |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 531370 |
102,600 |
Halten |
9.176,60 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 28,90 |
35,25 |
0,79 |
50,29 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 4,45 |
36,58 |
4,39 |
19,67 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 1,10 |
1,10 |
1,07 |
21.03.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 09.02.2024 |
08.05.2024 |
06.08.2024 |
12.12.2023 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -7,09% |
6,72% |
3,80% |
-17,56% |
|
|
Carl Zeiss Meditec AG DE0005313704